Why This Crocs Analyst Says Company Is Putting Its Best Foot Forward
In a recent annual survey, Crocs, Inc. (NASDAQ: CROX) was cited as among the fastest-growing brands among Gen Z.
Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer’s 20-Plus-Year Near Monopoly, Says Analyst
Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (primarily for disease prevention).
Analyst Highlights Asset-Backed Cannabis Loans In Chicago Atlantic’s REFI With Overweight Rating
Zuanic & Associates (Z&A) recently initiated coverage of Chicago Atlantic Real Estate Finance Inc. (NASDAQ: REFI) with an Overweight rating. Chicago Atlantic is an externally managed commercial mortgage real estate investment trust.
Investment Potential: Financial Performance, Portfolio And Growth Of Leading Public Sale-Leaseback Stock In Cannabis
Zuanic & Associates' latest report, which initiates coverage of New Lake Capital Partners (OTC: NLCP) with an Overweight rating explains their motivation. "As of the third quarter of 2023, its net real estate assets were valued at $375 million, a significant increase from $12
Strategic Analysis By Analyst: Diverse Outcomes For Fintech Stocks In Current Market Conditions
BMO Capital Markets analyst Rufus Hone initiated coverage on several fintech stocks.
Western Union Analyst Says It’s ‘Too Early To Bank On A Turnaround’
Shares of Western Union Co (NYSE: WU) lost around 5% over the last five trading sessions.
Nike Has ‘Stronger Revenue Growth Ahead,’ Says Bullish Goldman Sachs
Nike Inc (NYSE: NKE) offered heavy discounts, going up to 60% on even fresh stock, during Black Friday and Cyber Monday as bargain-conscious shoppers increased t
Undervalued VistaGen Therapeutics, Analyst Highlights Potential In Anxiety Treatment
William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety disorder (SAD) and other
Why Newly Listed Korro Bio Shares Are Gaining Today
H.C. Wainwright initiated coverage on Korro Bio Inc (NASDAQ: KRRO), a biotech company developing genetic medicines focused on editing ribonucleic acid (RNA) to treat various diseases.
Aerospace Industry Revival Favors These Two Stocks, Analysts Highlight Upswing Potential
Stifel analyst Bert W.